MEGAMIN ACTIV CHEMOTHERAPY HELP
Megamin has proved roborant effect and is making it easier for the patients to endure chemotherapy. For all tumor patients a dose of 1.8 g/day was ordered in the first week of application, to be gradually increased up to 2.6 g/day in the third week (exceptionally even up to 3.0 g in certain cases, depending on the general status of the patient, tumor size and location, G1, G2, G3 stages and serological and Tu marker findings). Patients with planocellular cancer of head and neck were receiving the standard chemotherapy protocol with cisplatine and 5-fluorouracil. The observations of our patients are showing the following lab parameters: Transaminase, especially SGPT, improvement in 22% cases, CRP values decreasing in 2.3% cases, while the Cyfra tumor marker is also decreasing in 0.8% cases.
The tumor which cause (ovarina cancer, prostate cancer, brest cancer, stomach cancer, liver cancer) is slightly improving in 0.4% cases, while other parameters remain almost unchanged, except for sedimentation, which is slightly slowed down. 34% of our tumor patients have gained weight, which is undoubtedly a proof of positive anabolic occurrences. All patients declare to feel fresher and stronger, that their strength is "coming back", that they are overcoming exertion much better.
We have also noticed that Megamin is having its best effect in the T1 and T2 stages (according to the WHO - TNM classification), while in the T3 and T4 stages it sometimes shows only a roborant effect in the sense of an improvement of the bodily resistance, whereas there is no significant influence of the tumor and the tumor growth.
Hear I quote the case of L.H., a 76 years old patient, where an almost complete tumor remission was established (95%). The case was a T2NoMx stadium larynx cancer. Neither chemotherapy nor radiation was proscribed for this patient. He was only and exclusively taking Megamin, 4.0g/day in the first year, followed by 1.8g/day, which does is still taking today.
Megamin is showing an exceptional feature which is the possibility to apply the Megamin powder on the tissue locally. It may be applied to exulcerated blooming metastases in the lymph nodes of the axillary and the inguinal regions of the neck.
By such an application in open and blooming metastases of the lymph nodes, which are strongly secerning, bleeding and badly stinking, all symptoms (ovarian cancer symptom, breast cancer symptom, prostate cancer symptom, liver cancer symptom, stomach cancer symptom) disappear and the metastases are very quickly “melting” and rapidly decreasing. In my opinion this is a direct proof of the Megamin inhibitory effect on the tumor expression. The quality of life for such patients is improved, they are psychologically stabilized and hope is stirred.
One doesnot need to emphasize here of how great importance this is for such patients. Rarely have we also administered Megamin in the internal and the surgical department.
In patients with chronic ulcerative colitis symptoms and signs of illness have improved. Less frequent and not any more bloody stools were observed and the patients have gained weight. In patients with mild cases of diabetes mellitus the need for insulin was significantly decreased, while in two patients with chronic hepatitis caused by hepatitis C virus we have had an obvious general physical progress.
In patients ill with breast cancer (planocellular carcinoma) Megamin was also applied after surgical therapy. Significant physical improvement and an improvement in terms of condition were observed, and the anemia as well as the bodily weight were improved.
We note that in these patients Megamin was dosed according to the same usual scheme (1. week 6 capsules of 300 mg per day + 0.6 g of powder; 2. week 8 capsules of 300 mg per day + 0.9 g of powder; 3. week 10 capsules of 300 mg per day + 1.2 g of powder).
As a rule the patients were taking this therapy well. As regards side effects, it was observed that the patients are complaining about a mild to stronger flatulence and meteorism, as well as frequent urination.
In several cases we have tried to administer Megamin to adolescents and children. We were dealing with two cases of leukemia and one case of glioblastoma in a 13 year old boy, but because it was impossible to implement the therapy for several reasons, we have given up the therapy after the first couple of days.
The Megamin therapy was not administered in pregnant women. Clinical observation and monitoring of tumor patients, who were taking adjuvant Megamin therapy according to the above mentioned scheme is leading us to the fact that Megamin has a roborant and an antioxidative effect in T1 and T2 stadium tumors, that it strengthens the overall resistance and thereby also the immunological systems of the body, which are indispensable in the fight against malignoma. We have further seen that concomitant taking of Megamin together with radiation and chemotherapy is having a better effect and is relieving the post-chemotherapy and the post-surgery symptoms.
Today we can say that Megamin Activ is mach better product than has Panceo, Imunofan, Galavit.
Finally we can conclude that Megamin is an excellent adjuvant preparation to the basic therapy.